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1. INTRODUCTION {#brb31149-sec-0005}
===============

White matter hyperintensity (WMH) is frequently viewed as hyperintensity signal on the T2‐weighted or fluid‐attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) sequences, which is closely relevant to ischemic stroke (Shim et al., [2015](#brb31149-bib-0027){ref-type="ref"}). Many investigators found that WMH is always associated with early neurological deterioration (END) and large infarct size in patients with acute ischemic stroke (AIS) after intravenous thrombolysis (IVT; Feng et al., [2014](#brb31149-bib-0005){ref-type="ref"}; Kongbunkiat et al., [2017](#brb31149-bib-0016){ref-type="ref"}; Zhong et al., [2016](#brb31149-bib-0038){ref-type="ref"}). They also observed that severe WMH is an independent risk factor for hemorrhagic transformation (HT) and poor functional outcomes after IVT in AIS patients (Gilberti et al., [2017](#brb31149-bib-0008){ref-type="ref"}; Kongbunkiat et al., [2017](#brb31149-bib-0016){ref-type="ref"}). However, its mechanisms and etiologies are still unclear. Previous studies suggested that the pathological mechanisms for WMH might be associated with vascular diseases including endothelial damage, arteriosclerosis, and Virchow--Robin space dilatation (Pantoni, [2010](#brb31149-bib-0024){ref-type="ref"}; Zhang et al., [2015](#brb31149-bib-0037){ref-type="ref"}). Moreover, other neuropathological mechanisms, such as severe demyelination, decreased oligodendrocytes, and the proliferation of glial cells (Nordahl et al., [2006](#brb31149-bib-0022){ref-type="ref"}), were also suggested. With the severity of WMH, self‐regulation dysfunction of microvascular circulation occurs, leading to thickening, stenosis, or occlusion of small arteries, and eventually leading to low reperfusion of brain tissue that transforms into infarction (Shim et al., [2015](#brb31149-bib-0027){ref-type="ref"}). These findings also suggest other potential mechanisms such as blood--brain barrier disruption and microglial cell‐related inflammatory processes (Wardlaw, Smith, & Dichgans, [2013](#brb31149-bib-0035){ref-type="ref"}).

According to the site, WMH is often classified into deep white matter hyperintensity (DWMH) and periventricular hyperintensity (PVH). At present, it is widely accepted that WMH lesion at different locations has different mechanisms (Fazekas et al., [1993](#brb31149-bib-0004){ref-type="ref"}). For example, PVH is associated with neurofibrillary tangles and arteriosclerosis (Bahrani et al., [2017](#brb31149-bib-0001){ref-type="ref"}; Gao et al., [2014](#brb31149-bib-0007){ref-type="ref"}). Yet, DWMH is relevant to microinfarction and cerebral hemorrhage (Gao et al., [2014](#brb31149-bib-0007){ref-type="ref"}; Shim et al., [2015](#brb31149-bib-0027){ref-type="ref"}). Based on these data, we hypothesized that the efficacy of IVT in AIS patients with WMH at different sites may be different. Thus, the objective of this study was to evaluate the efficacy of IVT in AIS patients with PVH or DWMH.

2. METHODS {#brb31149-sec-0006}
==========

2.1. Participants {#brb31149-sec-0007}
-----------------

In this study, a total of 113 AIS patients were consecutively enrolled from department of neurology in Changzhou No.2 People\'s Hospital between January 2013 and April 2017. All patients were categorized into two groups according to the site of WMH. Of these patients, 51 patients were confirmed with DWMH and 62 patients with PVH by the MRI scan. According to the patients whether or not received IVT, they were further divided into two respective subgroups: the thrombolysis group and the control group. The control patients did not receive IVT because they did not meet the requirement of the therapeutic window for IVT or refused IVT or had other contraindications to IVT**.** The inclusion criteria were as follows: (a) first‐ever ischemic stroke diagnosed by the experienced neurological physician based on diffusion‐weighted imaging (DWI); (b) ranged 6--16 in baseline National Institutes of Health Stroke Scale (NIHSS) score; (c) receiving rt‐PA IVT within 4.5‐hr from onset in the thrombolysis group or not receiving IVT within 6‐hr from onset at admission in the control group; (d) underwent MRI and magnetic resonance angiography (MRA) and CT during hospitalization; (e) ranged 2--3 score by the Fazekas scale for PVH or DWMH; and (f) obtained written informed consent form from participants. The exclusion criteria were as follows: (a) treatment with arterial thrombolysis or IVT before admission; (b) a history of multiple infarctions; (c) failure to undergo MRI and MRA or poor imaging quality; and (d) a diagnosis of hemorrhagic infarct. This retrospective study was approved by the Ethics Committee of Changzhou No. 2 People\'s Hospital.

2.2. Treatments {#brb31149-sec-0008}
---------------

Besides routine treatments for cerebral infarction such as antiplatelet, brain protection, lipid‐lowering, stabilizing plaques, the patients with AIS in the thrombolysis group received the recombinant tissue plasminogen activator (rt‐PA, 0.9 mg/kg up to a maximum of 90 mg). Ten percent of total dosage of rt‐PA was delivered by intravenous injection within one minute, while the remaining was administrated by intravenous drip within 1 hr. The control group only received routine treatment.

2.3. Clinical data collection {#brb31149-sec-0009}
-----------------------------

Clinical data such as demographical data, risk factors for stroke, including hypertension, diabetes mellitus, hyperlipidemia, coronary artery disease, atrial fibrillation, transient ischemic attack (TIA), the history of smoking and drinking, and the time of onset to treatment, were collected. The neurological deficit was assessed by the National Institute of Health Stroke Scale (NIHSS) at admission and 24 hr later; END was defined as an increase of ≥1 point on the motor NIHSS score or ≥2 points on the total NIHSS score 72 hr after admission (Jeong, Kim, Yang, Han, & Bae, [2015](#brb31149-bib-0012){ref-type="ref"}). The motor function was scored using Fugl‐Meyer rating scale (FMS) at admission and 90‐day follow‐up (we chose FMS but not mRS based on the following reasons: Cerebral infarction caused by middle cerebral artery occlusion had a greater influence on motor function of limbs; and FMS is more accurate and reliable than mRS score in evaluating limb motor function (Gladstone, Danells, & Black, [2002](#brb31149-bib-0009){ref-type="ref"}). During 90‐day follow‐up, hemorrhagic transformation (HT) and symptomatic intracranial hemorrhage (sICH) defined by ECASS II (Larrue, Kummer, Muller, & Bluhmki, [2001](#brb31149-bib-0017){ref-type="ref"}), stroke recurrence, and death were recorded. One neurologist carried out the evaluation of the neurological function and limb function prognosis of the enrolled patients and was blinded to the treatment.

2.4. Endpoint events during follow‐up {#brb31149-sec-0010}
-------------------------------------

All patients were followed up for 7, 30, 60, and 90 days after discharge. The major endpoint events included recurrent stroke and death; the secondary endpoint events were other vascular events. Stroke recurrence was defined according to a previous reference (Erdur et al., [2015](#brb31149-bib-0003){ref-type="ref"}) as a new neurological deficit lasting for more than 24 hr; the new neurological deficit occurred 24 hr after first‐ever event, not due to other systemic or neurological caused, confirmed by cranial MRI.

2.5. Imaging protocol {#brb31149-sec-0011}
---------------------

Cerebral MRI and magnetic resonance angiography (MRA) were performed using a 3.0‐T system (Achieva 3.0; Philips, Royal Philips, the Netherlands). At admission, all participants underwent MRI including DWI sequence and FLAIR sequence. We assessed WMHs by using the Fazekas scale for PVH (0--3 score) or for DWMH (0--3 score) on axial FLAIR images. PVH indicated WMHs in contact with the ventricular wall graded from 0 to 3 as described previously (Shrestha et al., [2009](#brb31149-bib-0028){ref-type="ref"}). DWMH indicated that WMHs appeared in the deep white matter graded from 0 to 3 as described previously (Gao, et al., [2014](#brb31149-bib-0007){ref-type="ref"}) and isolated from the ventricular wall by a strip of normal‐appearing white matter. We included patients with only PVH or only DWMH scored 2--3 points using the Fazekas scale, while patients with the combination of PVH and DWMH were excluded. One neuroradiologist performed the classification of WMH site and was blinded to the treatment.

2.6. Statistics analysis {#brb31149-sec-0012}
------------------------

The Statistical Package for the Social Sciences (SPSS) version 20.0 software package was used for statistical analysis. Continuous variables were presented as mean ± standard deviation (*SD*) and analyzed by using independent‐samples two‐tailed *t* test. Categorical variables were shown as proportions or frequency and analyzed by using chi‐square test or Fisher\'s exact test. The survival rate of patients with DWMH and patients with PVH without major endpoint events was shown by Kaplan--Meier curve. Further, multivariable Cox regression model was used to analyze relevant risk factors for stroke recurrence. Previous studies showed that age, baseline NIHSS score, baseline FMS score, hypertension, diabetes, coronary heart disease, atrial fibrillation, and transient ischemic attack are risk factors for long‐term prognosis of patients with cerebral infarction (Johnston et al., [2000](#brb31149-bib-0014){ref-type="ref"}; Kimura et al., [2009](#brb31149-bib-0015){ref-type="ref"}; Parsons et al., [2002](#brb31149-bib-0025){ref-type="ref"}), and thus, these independent variables were included in the multivariate regression. Additionally, WHM and IVT were the focus of this study and thus were also included in the regression. *p* Value \<0.05 was considered statistically significant.

3. RESULTS {#brb31149-sec-0013}
==========

3.1. Characteristics of patients {#brb31149-sec-0014}
--------------------------------

We eventually recruited 113 AIS patients with a mean age of 67.5 ± 10.9 years into this study. Of total patients, 62 (54.9%) patients exhibited PVH, while 51 (45.1%) patients showed DWMH. In the whole cohort, 19 (16.8%) patients and 10 (8.9%) patients showed END and HT, respectively. Patients with DWMH had a higher rate of occurrence in END and HT as compared to patients with PVH. Characteristics of enrolled patients and comparisons in clinical outcomes between PVH patients and DWMH patients are presented in Table [1](#brb31149-tbl-0001){ref-type="table"}.

###### 

Characteristics of enrolled patients and comparisons in clinical outcomes between PVH and DWMH patients

  Characteristics                      All patients (*n* = 113)   PVH (*n* = 62)   DWMH (*n* = 51)   *t/x* ^2^   *p*
  ------------------------------------ -------------------------- ---------------- ----------------- ----------- -----------
  Age (years, mean ± *SD*)             67.5 ± 10.9                68.4 ± 10.5      66.4 ± 11.4       0.770       0.382
  Male, *N* (%)                        67 (59.3)                  34 (54.8)        33 (64.7%)        1.129       0.288
  Baseline NIHSS score (mean ± *SD*)   9.3 ± 3.5                  9.4 ± 3.7        9.2 ± 3.5         0.844       0.360
  Baseline FMS score (mean ± *SD*)     85.3 ± 8.5                 84.9 ± 8.7       85.8 ± 8.1        1.229       0.270
  Risk factors                                                                                                   
  Hypertension, *N* (%)                91 (80.5)                  44 (71.0)        47 (92.2)         8.013       **0.005**
  Diabetes mellitus, *N* (%)           53 (46.9)                  28 (45.2)        25 (49.0)         0.167       0.683
  Hyperlipidemia, *N* (%)              31 (27.4)                  17 (27.4)        14 (27.5)         0.000       0.997
  Coronary artery disease, *N* (%)     12 (10.6)                  6 (9.7)          6 (11.8)          0.128       0.720
  Arterial fibrillation, *N* (%)       12 (10.6)                  7 (11.3)         5 (9.8)           0.065       0.799
  TIA, *N* (%)                         11 (9.7)                   5 (8.1)          6 (11.8)          0.434       0.510
  Smoking, *N* (%)                     36 (31.9)                  19 (30.6)        17 (33.3)         0.093       0.760
  Drinking, *N* (%)                    19 (16.8)                  12 (19.4)        7 (13.7)          0.634       0.426
  Clinical variables                                                                                             
  END, *N* (%)                         19 (16.8)                  8 (12.9)         11 (21.6)         1.502       0.220
  HT, *N* (%)                          10 (8.9)                   4 (6.5)          6 (11.8)          0.979       0.322
  sICH, *N* (%)                        4 (3.5)                    2 (3.2)          2 (3.9)           0.039       0.842
  Recurrence of stroke, *N* (%)        13 (11.5)                  11 (17.7)        2 (3.9)           5.250       **0.022**
  90‐day death, *N* (%)                5 (4.4)                    2 (3.2)          3 (5.9)           0.465       0.495
  90‐day FMS score (mean ± *SD*)       86.6 ± 21.2                83.1 ± 24.8      90.9 ± 14.7       7.921       **0.006**
  Thrombolysis selection                                                                                         
  Thrombolysis, *N* (%)                49 (43.4)                  27 (43.5)        22 (43.1)         0.002       0.965
  No thrombolysis, *N* (%)             64 (56.6)                  35 (56.5)        29 (56.9)                     

Statistical significances are indicated in bold.

DWMH: deep white matter hyperintensity; END: early neurological deterioration; FMS: Fugl‐Meyer rating scale; HT: hemorrhagic transformation; NIHSS: National Institute of Health Stroke Scale; PVH: periventricular hyperintensity; *SD*: standard deviation; sICH: symptomatic intracranial hemorrhage; TIA: transient ischemic attack.
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3.2. Comparisons in clinical information and clinical outcomes between PVH patients and DWMH patients in the thrombolysis group or in the control group {#brb31149-sec-0015}
-------------------------------------------------------------------------------------------------------------------------------------------------------

Among PVH patients, 27 patients (43.5%) received IVT, while 35 patients (56.5%) failed to receive IVT due to beyond therapeutic window (*n* = 25), refusing IVT (*n* = 8), or contraindications (*n* = 2). Of 51 DWMH patients, 22 patients (43.1%) received IVT, and 29 patients (56.9%) failed to receive IVT due to beyond therapeutic window (*n* = 17), refusing IVT (*n* = 9), or contraindications (*n* = 3; Table [2](#brb31149-tbl-0002){ref-type="table"}). By comparison, there were no significant differences in age, sex, diabetes mellitus, hyperlipidemia, coronary artery disease, arterial fibrillation, TIA, smoking, drinking, baseline NIHSS score, 24‐hr NIHSS score, baseline FMS score, and 90‐day FMS score between PVH patients and DWMH patients in the thrombolysis group or in the control group (Table [2](#brb31149-tbl-0002){ref-type="table"}). But DWMH patients had a higher occurrence of hypertension than PVH patients in the thrombolysis group and in the control group (Table [2](#brb31149-tbl-0002){ref-type="table"}). Furthermore, DWMH patients had a higher risk of END and HT than PVH patients in the thrombolysis group but not in the control group (Table [2](#brb31149-tbl-0002){ref-type="table"}). In contrast, PVH patients had a higher risk of recurrent stroke than DWMH patients in the control group, but not in the thrombolysis group (Table [2](#brb31149-tbl-0002){ref-type="table"}). However, there were no significant differences in sICH and 90‐day death between PVH patients and DWMH patients in the two subgroups (Table [2](#brb31149-tbl-0002){ref-type="table"}). Therefore, these data suggested that the efficacy of intravenous thrombolysis is different in AIS patients with WMH at different sites.

###### 

Baseline data and clinical features of patients with white matter hyperintensity at different sites

  Characteristics                      Thrombolysis   *t/x* ^2^     *p*                                            Control     *t/x* ^2^     *p*                                                          
  ------------------------------------ -------------- ------------- ---------------------------------------------- ----------- ------------- ------------- ---------------------------------------------- -----------
  Age (mean ± *SD*)                    68.0 ± 12.3    63.2 ± 12.7   1.334[a](#brb31149-note-0006){ref-type="fn"}   0.189       68.8 ± 8.9    68.8 ± 10.0   0.018[a](#brb31149-note-0006){ref-type="fn"}   0.986
  Male, *N* (%)                        18 (66.7)      16 (72.7)     0.210                                          0.647       16 (45.7)     17 (58.6)     1.058                                          0.304
  Risk factors                                                                                                                                                                                            
  Hypertension, *N* (%)                18 (66.7)      20 (90.9)     4.412                                          **0.036**   26 (74.3)     27 (93.1)     4.274                                          **0.039**
  Diabetes mellitus, *N* (%)           9 (33.3)       9 (40.9)      0.299                                          0.584       19 (54.3)     16 (55.2)     0.005                                          0.943
  Hyperlipidemia, *N* (%)              7 (25.9)       5 (22.7)      0.067                                          0.796       10 (28.6)     9 (31.0)      0.046                                          0.830
  Coronary artery disease, *N* (%)     3 (11.1)       2 (9.1)       0.054                                          0.816       3 (8.6)       4 (13.8)      0.442                                          0.506
  Arterial fibrillation, *N* (%)       3 (11.1)       2 (9.1)       0.054                                          0.816       4 (11.4)      3 (10.3)      0.019                                          0.890
  TIA, *N* (%)                         2 (7.4)        4 (18.2)      1.313                                          0.252       3 (8.6)       2 (6.9)       0.062                                          0.803
  Smoking, *N* (%)                     10 (37.0)      9 (40.9)      0.077                                          0.782       9 (25.7)      8 (27.6)      0.028                                          0.866
  Drinking, *N* (%)                    6 (22.1)       4 (18.2)      0.123                                          0.726       6 (17.1)      3 (10.3)      0.620                                          0.431
  Baseline NIHSS score (mean ± *SD*)   10.2 ± 4.0     9.0 ± 3.8     1.130[a](#brb31149-note-0006){ref-type="fn"}   0.264       8.8 ± 3.3     8.9 ± 2.8     0.132[a](#brb31149-note-0006){ref-type="fn"}   0.895
  24‐hr NIHSS score (mean ± *SD*)      8.2 ± 7.0      7.9 ± 5.4     0.155[a](#brb31149-note-0006){ref-type="fn"}   0.877       8.8 ± 3.7     9.0 ± 4.0     0.272[a](#brb31149-note-0006){ref-type="fn"}   0.787
  Baseline FMS score (mean ± *SD*)     83.0 ± 9.1     86.2 ± 8.7    1.262[a](#brb31149-note-0006){ref-type="fn"}   0.213       86.4 ± 8.3    85.5 ± 8.0    0.464[a](#brb31149-note-0006){ref-type="fn"}   0.644
  90‐day FMS score (mean ± *SD*)       80.9 ± 26.1    89.7 ± 21.3   1.284[a](#brb31149-note-0006){ref-type="fn"}   0.205       84.8 ± 24.3   91.7 ± 7.4    1.604[a](#brb31149-note-0006){ref-type="fn"}   0.116
  Clinical variables                                                                                                                                                                                      
  END, *N* (%)                         3 (11.1)       8 (36.4)      4.510                                          **0.034**   5 (14.3)      3 (10.3)      0.228                                          0.633
  HT, *N* (%)                          1 (3.7)        5 (22.7)      4.298                                          **0.038**   3 (8.6)       1 (3.4)       0.750                                          0.386
  sICH, *N* (%)                        1 (3.7)        1 (4.5)       0.022                                          0.883       1 (2.9)       1 (3.4)       0.018                                          0.893
  Recurrent stroke, *N* (%)            4 (14.8)       1 (4.5)       1.507                                          0.220       7 (20.0)      1 (3.4)       4.499                                          **0.034**
  90‐day death, *N* (%)                2 (7.4)        2 (9.1)       0.046                                          0.831       0 (0.0)       1 (3.4)       1.602                                          0.206

Statistical significances are indicated in bold.

DWMH: deep white matter hyperintensity; END: early neurological deterioration; FMS: Fugl‐Meyer rating scale; HT: hemorrhagic transformation; NIHSS: National Institute of Health Stroke Scale; PVH: periventricular hyperintensity; *SD*: standard deviation; sICH: symptomatic intracranial hemorrhage; TIA: transient ischemic attack.

*t* test; others: chi‐square value.
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3.3. Comparisons between the two subgroups in PVH patients or DWMH patients {#brb31149-sec-0016}
---------------------------------------------------------------------------

As shown in Table [3](#brb31149-tbl-0003){ref-type="table"}, there were no significant differences in age, sex, risk factors for stroke, baseline NIHSS score, and baseline FMS score between the thrombolysis group and the control group in PVH patients and DWMH patients. By comparison, in either PVH patients or DWMH patients, there were no significant differences in 24‐hr NIHSS score, sICH, recurrent stroke, and 90‐day death (Table [3](#brb31149-tbl-0003){ref-type="table"}). Although there was no significant difference in END and HT between the thrombolysis group and the control group in PVH patients, DWMH patients undergoing IVT had a higher risk of END and HT (Table [3](#brb31149-tbl-0003){ref-type="table"}). Moreover, the two subgroups displayed a similar 90‐day FMS score (Table [3](#brb31149-tbl-0003){ref-type="table"}). Collectively, these results showed that DWMH patients and PVH patients differentially benefited from IVT.

###### 

Comparison of baseline and clinical data between subgroup in patients with PVH and DWMH

  Characteristics                      PVH           *t/x* ^2^     *p*                                            DWMH    *t/x* ^2^     *p*                                                          
  ------------------------------------ ------------- ------------- ---------------------------------------------- ------- ------------- ------------- ---------------------------------------------- -----------
  Age (mean ± *SD*)                    68.0 ± 12.3   68.8 ± 8.9    1.603[a](#brb31149-note-0009){ref-type="fn"}   0.210   63.2 ± 12.7   68.8 ± 10.0   0.816[a](#brb31149-note-0009){ref-type="fn"}   0.371
  Male, *N* (%)                        18 (66.7)     16 (45.7)     2.702                                          0.100   16 (72.7)     17 (58.6)     1.090                                          0.296
  Risk factors                                                                                                                                                                                       
  Hypertension, *N* (%)                18 (66.7)     26 (74.3)     1.575                                          0.209   20 (90.9)     27 (93.1)     0.083                                          0.774
  Diabetes mellitus, *N* (%)           9 (33.3)      19 (54.3)     2.702                                          0.100   9 (40.9)      16 (55.2)     1.018                                          0.313
  Hyperlipidemia, *N* (%)              7 (25.9)      10 (28.6)     0.054                                          0.817   5 (22.7)      9 (31.0)      0.433                                          0.510
  Coronary artery disease, *N* (%)     3 (11.1)      3 (8.6)       0.112                                          0.738   2 (9.1)       4 (13.8)      0.272                                          0.602
  Arterial fibrillation, *N* (%)       3 (11.1)      4 (11.4)      0.002                                          0.969   2 (9.1)       3 (10.3)      0.022                                          0.881
  TIA, *N* (%)                         2 (7.4)       3 (8.6)       0.028                                          0.867   4 (18.2)      2 (6.9)       1.528                                          0.216
  Smoking, *N* (%)                     10 (37.0)     9 (25.7)      0.919                                          0.338   9 (40.9)      8 (27.6)      0.999                                          0.318
  Drinking, *N* (%)                    6 (22.1)      6 (17.1)      0.252                                          0.616   4 (18.2)      3 (10.3)      0.642                                          0.423
  Baseline NIHSS score (mean ± *SD*)   10.2 ± 4.0    8.8 ± 3.3     1.492[a](#brb31149-note-0009){ref-type="fn"}   0.141   9.0 ± 3.8     8.9 ± 2.8     0.026[a](#brb31149-note-0009){ref-type="fn"}   0.980
  24‐hr NIHSS score (mean ± *SD*)      8.2 ± 7.0     8.8 ± 3.7     0.417[a](#brb31149-note-0009){ref-type="fn"}   0.679   7.9 ± 5.4     9.0 ± 4.0     0.886[a](#brb31149-note-0009){ref-type="fn"}   0.380
  Baseline FMS score (mean ± *SD*)     83.0 ± 9.1    86.4 ± 8.3    1.512[a](#brb31149-note-0009){ref-type="fn"}   0.136   86.3 ± 8.7    85.5 ± 8.0    0.352[a](#brb31149-note-0009){ref-type="fn"}   0.726
  90‐day FMS score (mean ± *SD*)       80.9 ± 26.1   84.8 ± 24.3   0.609[a](#brb31149-note-0009){ref-type="fn"}   0.545   89.7 ± 21.3   91.7 ± 7.4    0.471[a](#brb31149-note-0009){ref-type="fn"}   0.640
  Clinical variables                                                                                                                                                                                 
  END, *N* (%)                         3 (11.1)      5 (14.3)      0.138                                          0.710   8 (36.4)      3 (10.3)      5.050                                          **0.025**
  HT, *N* (%)                          1 (3.7)       3 (8.6)       0.633                                          0.426   5 (22.7)      1 (3.4)       4.664                                          **0.031**
  sICH, *N* (%)                        1 (3.7)       1 (2.9)       0.035                                          0.852   1 (4.5)       1 (3.4)       0.040                                          0.842
  Recurrent stroke, *N* (%)            4 (14.8)      7 (20.0)      0.284                                          0.594   1 (4.5)       1 (3.4)       0.040                                          0.842
  90‐day death, *N* (%)                2 (7.4)       0 (0.0)       3.412                                          0.065   2 (9.1)       1 (3.4)       0.716                                          0.398

Statistical significances are indicated in bold.

DWMH: deep white matter hyperintensity; END: early neurological deterioration; FMS: Fugl‐Meyer rating scale; HT: hemorrhagic transformation; NIHSS: National Institute of Health Stroke Scale; PVH: periventricular hyperintensity; *SD*: standard deviation; sICH: symptomatic intracranial hemorrhage; TIA: transient ischemic attack.

*t* test; others: chi‐square value.
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3.4. Association between stroke recurrence and PVH or DWMH {#brb31149-sec-0017}
----------------------------------------------------------

During 90‐day follow‐up, the incidence of stroke recurrence was 11.5%. Kaplan--Meier analysis revealed that there was significant difference in cumulative probability of major endpoint events between PVH patients and DWMH patients (log‐rank test \[Mantel--Cox\]; chi‐square = 4.252; *p* = 0.039; Figure [1](#brb31149-fig-0001){ref-type="fig"}). Furthermore, considering PVH, age, baseline NIHSS score, baseline FMS score, sex, hypertension, diabetes mellitus, coronary artery disease, arterial fibrillation, TIA, and thrombolytic selection, the multivariate Cox model analysis showed that PVH and TIA are two independent predictors of stroke recurrence for patients with AIS (Table [4](#brb31149-tbl-0004){ref-type="table"}).

![Kaplan--Meier survival curves for patients with no major endpoint events by periventricular hyperintensity (PVH) and deep white matter hyperintensity (DWMH; *p* value \[log‐rank\] = 0.039)](BRB3-8-e01149-g001){#brb31149-fig-0001}

###### 

Multivariate Cox regression analysis on independent predictors for stroke recurrence in AIS patients

  Characteristics           HR      95% CI            *p*
  ------------------------- ------- ----------------- -----------
  PVH                       5.395   1.104 \~ 26.359   **0.037**
  Age                       1.040   0.966 \~ 1.120    0.295
  Baseline NIHSS score      1.095   0.705 \~ 1.701    0.686
  Baseline FMS score        1.013   0.834 \~ 1.229    0.899
  Sex                       1.334   0.336 \~ 5.305    0.682
  Hypertension              3.558   0.387 \~ 32.746   0.262
  Diabetes mellitus         1.873   0.454 \~ 7.724    0.385
  Coronary artery disease   0.432   0.040 \~ 4.661    0.489
  Arterial fibrillation     3.020   0.762 \~ 11.970   0.116
  TIA                       6.905   1.367 \~ 34.879   **0.019**
  Thrombolytic selection    0.609   0.161 \~ 2.304    0.465

Statistical significances are indicated in bold.

FMS: Fugl‐Meyer rating scale; NIHSS: National Institute of Health Stroke Scale; PVH: periventricular hyperintensity; TIA: transient ischemic attack.
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4. DISCUSSION {#brb31149-sec-0018}
=============

Before this study, our previous data showed that WHM influences the therapeutic effect and prognosis of patients with cerebral infarction in the middle cerebral artery blood supply area after IVT (Supporting Information Table [S1](#brb31149-sup-0001){ref-type="supplementary-material"}). In this study, we further showed that the efficacy of IVT is different in AIS patients with WMH at different sites. As compared to PVH patients, DWMH patients had a higher risk of END and HT after IVT. Specifically, PVH patients had a higher risk of recurrent stroke and a poorer motor function outcome relative to DWMH patients. By adjustment of confounding factors, multivariate Cox regression model revealed that PVH and TIA are two independent risk factors for recurrent stroke in AIS patients.

White matter hyperintensity, as an important type of cerebral small vessel disease, has attracted much attention recently. Although its mechanisms are unclear, increasing evidence on the association between MRI and pathology suggested that WMH at different sites might have different pathological mechanisms. Specifically, DWMH was associated with hypertension‐related atherosclerosis and severe vascular stenosis (Deicken, Reus, Manfredi, & Wolkowitz, [1991](#brb31149-bib-0002){ref-type="ref"}), leading to prolonged hypoperfusion of distal small arteries (Spilt et al., [2006](#brb31149-bib-0031){ref-type="ref"}). Moreover, the deep WM is located in the ischemic sensitive area with less collateral circulation. Eventually, deep WM reflects a chronic ischemic change. This was in line with our results showing that DWMH patients had a higher occurrence of hypertension, had a higher risk of HT, and were prone to END after IVT as compared to PVH patients. The DWM is mainly supplied by the branches of the middle cerebral artery and is susceptible to risk factors such as hypertension, consistent with our conclusion. Long‐term hypertension leads to vitreous degeneration of arterioles, thickening of the walls, and stenosis of the lumen, resulting in chronic ischemic, hypoxia of distal small arteries, further impaired vascular endothelium, increased vascular permeability, and various pathological changes in white matter (Grueter & Schulz, [2012](#brb31149-bib-0011){ref-type="ref"}; Uh, Yezhuvath, Cheng, & Lu, [2010](#brb31149-bib-0033){ref-type="ref"}; Wardlaw, Sandercock, Dennis, & Starr, [2003](#brb31149-bib-0034){ref-type="ref"}). Once cerebral infarction occurs in the blood supply area of the middle cerebral artery, the ischemic penumbra around the infarct cannot be saved timely, and the distal arteries at lesioned sites display prolonged hypoperfusion which further aggravates injury of the vascular wall, the infarct size will increase and the impairment of neurological functions will aggravate. Prolonged reperfusion time and a large infarct size also increase the risk of intracranial hemorrhage. In addition, increasing evidence shows that exogenous rt‐PA can further destroy the damaged blood--brain barrier, thereby affecting the hemorrhagic transformation and prognosis of patients with cerebral infarction (Ji et al., [2017](#brb31149-bib-0013){ref-type="ref"}; Liu et al., [2018](#brb31149-bib-0018){ref-type="ref"}). Previous studies showed that intracranial hemorrhage and increased infarct size are the main risk factors for the early deterioration of neurological function in patients with cerebral infarction after IVT, consistent with our findings (Seners, Turc, Oppenheim, & Baron, [2015](#brb31149-bib-0026){ref-type="ref"}). Together, **t**hese studies further explain the early deterioration of neurological functions and the risk of intracranial hemorrhage in cerebral infarction patients with DWMH after IVT.

In contrast, PVH has different pathological mechanisms. Plasma proteins have been found around lateral ventricles. WM lesion at these locations might not be entirely attributed to vascular factors, but likely due to the obstruction of blood circulation in the dense venous network around the ventricles, leading to higher water content in the area. Moreover, the destruction of the ependyma of lateral ventricle and the presence of glial hyperplasia of granular ependyma might lead to damage of blood--brain barrier and the leakage of cerebrospinal fluid into the periventricular region, aggravating the edema of surrounding brain tissue and nerve demyelination (Franklin & Ffrench‐Constant, [2008](#brb31149-bib-0006){ref-type="ref"}; Nagai, Hoshide, & Kario, [2012](#brb31149-bib-0021){ref-type="ref"}). Furthermore, Grafton et al. ([1991](#brb31149-bib-0010){ref-type="ref"}) also found that PVH is associated with myelin pallor, gliosis, and Virchow--Robin space dilatation, significantly different from the pathology of DWMH. Again, Murray et al. ([2012](#brb31149-bib-0020){ref-type="ref"}) also reported that there are more cavity formation and medulla loss in the surrounding PVH. In contrast, at the DWMH area, loss of axon, astrocyte, microglia, and oligodendrocyte was minimal. These pathological mechanisms partly at least explain a poorer recovery of motor function outcome in patients with PVH. Due to the obstruction of blood circulation in the venous network for a long time, the perivascular activity and reactivity gradually decline and self‐regulation dysfunction of cerebral microcirculation occurs, leading to the vulnerability of small vessels and further edema and infarction of surrounding brain tissue. Therefore, these are attributed to a higher risk of recurrent stroke in patients with PVH. And the latter is directly associated with the deterioration of neurological function and the poor recovery of motor function outcome at 90‐day follow‐up. Moreover, PVH was associated with the damage of corticospinal tracts, which are vital for motor function. Conceivably, PVH may be involved in the recovery of motor function in AIS patients with IVT treatment. A few of studies showed that white matter tracts located in the PVH always involve long contact fiber, whereas those located in the DWMH are more likely to involve short contact fiber (Bahrani et al., [2017](#brb31149-bib-0001){ref-type="ref"}; Smith et al., [2016](#brb31149-bib-0030){ref-type="ref"}; Spilt et al., [2006](#brb31149-bib-0031){ref-type="ref"}). This difference may result in the different recovery of motor function outcome.

However, there was no significant difference in 90‐day motor function outcome between PVH patients and DWMH patients after IVT. This might be related to the pathological mechanisms of WMH, including demyelination, axonal loss, oligodendrocytes, and astrocytic hyperplasia (Moon et al., [2017](#brb31149-bib-0019){ref-type="ref"}). It is well known that the recovery of neurological function in AIS patients depends on how the extensive neural network of the patients compensates for the damaged structures. WMH is associated with severe damage to the integrity of the brain functional network, resulting in a significant decrease in the compensatory function of the brain, and thus affecting the recovery of neurological functions (Nordahl et al., [2006](#brb31149-bib-0022){ref-type="ref"}). Moreover, it was reported that brain tissue perfusion was reduced by more than thirty percent in WMH patients (O\'Sullivan et al., [2002](#brb31149-bib-0023){ref-type="ref"}), leading to poor vascular reactivity. Therefore, when AIS occurred, the reduced ischemic tolerance of brain tissue around the infarct site would result in the increase of infarct size, and eventually poor motor function outcome. Moreover, the severity of WMH might represent the overall lesion extent of small vessels, thereby affecting the prognosis after IVT. Finally, exogenous rt‐PA also increases the risk of HT, thereby increasing infarct size, aggravating the impairment of neurological function (Simao, Ustunkaya, Clermont, & Feener, [2017](#brb31149-bib-0029){ref-type="ref"}), and naturally affecting the recovery of motor function outcome.

Notably, limitations of our study need consideration. First, our study was a retrospective single‐center study with a small number of patients. Thus, our findings need to be confirmed by a multicenter study with a large sample size. Second, we assessed the degree of WMH and the site of WMH using MRI; thus, the subjective factor and selection bias could not completely be excluded. Third, we failed to evaluate recanalization status and cerebral microbleed burden（because only a small number of patients (12.4%) had MRI images with SWI sequence (Supporting Information Figure [S2](#brb31149-sup-0001){ref-type="supplementary-material"}), we could not make further analysis (Tsivgoulis et al., [2016](#brb31149-bib-0032){ref-type="ref"}), which was associated with stroke functional outcome in previous studies (Zhang et al., [2017](#brb31149-bib-0036){ref-type="ref"}). Fourth, since HT occurred in a small number of patients, we failed to divide into subgroups according to the severity. Thus, mild types of HT which may be often clinically irrelevant could be not excluded. Fifth, confidence intervals in the multivariable analysis were very wide with the lower margin value close to 1 due to some uncertainties from a limited sample size.

5. CONCLUSION {#brb31149-sec-0019}
=============

In conclusion, this study showed that WMH at different sites might be associated with different mechanisms, which influences the efficacy of IVT and the prognosis in AIS patients. Patients with DWMH but not with PVH were associated with END and a higher risk of HT after IVT. During 90‐day follow‐up, patients with PVH but not with DWMH had a higher risk of recurrent stroke and a poorer recovery of motor function outcome. However, there was no significant difference in the recovery of motor function between patients with PVH and patients with DWMH after IVT.
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